FOSUN HEALTH Logo

Breast Cancer Treatment

catalogue

Breast Cancer Treatment

Breast Cancer Treatment

Treatment is chosen from two things at once — how far the disease has gone and what the tumour carries — and from a third that patients rarely see written down: what you want to be able to do while you are being treated.

Treatment by stage: the sequence, not just the list

What distinguishes one breast cancer plan from another is rarely which treatments are available; it is the order in which they are given. The table below sets out the usual sequence. Every row carries exceptions, and the exceptions are decided by the receptor profile and by how the tumour responds.

Stage Usual sequence What decides the details
0 — in situ Breast-conserving surgery with clear margins, then radiotherapy in most cases Extent of the in situ disease and its grade; receptor status for the endocrine decision
I–II — early invasive Surgery first (breast-conserving where possible) with sentinel node assessment, then radiotherapy, then drugs Receptor and HER2 status, Ki-67, tumour size, node involvement, and gene-expression testing where it applies
II–III — selected tumours Drug treatment first, then surgery, then radiotherapy and remaining drug treatment HER2 positivity, triple-negative status, tumour size relative to breast size, and the response seen on imaging
III — locally advanced Systemic therapy to shrink the disease, then surgery, then radiotherapy How much the tumour shrinks; whether the skin or chest wall is involved; nodal response
IV — metastatic Systemic therapy as the backbone, in successive lines, with local treatment for specific sites The molecular profile at the time of progression, symptoms, and which organs are involved
Isolated recurrence Local treatment to the involved site, with systemic therapy continued or adjusted Number and location of involved sites; whether the disease is otherwise stable

The words "you need a mastectomy" are not always the end of the discussion. For some locally advanced tumours, drug treatment given first shrinks the disease enough that breast-conserving surgery becomes possible. Whether that is realistic in your case is answered by the response seen on imaging after the first cycles, not by the size of the tumour at diagnosis.

Surgery: removing the cancer, preserving the breast

Breast surgery has two jobs that were once treated as separate and are now planned together: removing the cancer completely, and leaving a breast the patient recognises. Where both can be achieved, both should be.

Keeping the breast: conservation and oncoplastic techniques

"I have a tumour. Can it be removed without changing how I look?"

Breast-conserving surgery removes the tumour with a clear margin and is followed by radiotherapy. Where the removed volume would leave a visible deformity, oncoplastic surgery reshapes the remaining breast tissue in the same operation to restore contour and symmetry — extending what can be conserved to tumours that would once have required a mastectomy. Where mastectomy is necessary, nipple-sparing mastectomy with immediate reconstruction preserves the skin envelope and the nipple-areola complex, so the patient wakes with a reconstructed breast already in place rather than facing a second operation and a period without one.

  • Clear margins
  • Contour restored in the same operation
  • Sentinel node assessment at the same time
  • Radiotherapy planned around the result

Where an operation is not the right first move

"I cannot or will not have surgery. Is there another way?"

For a small, well-localised tumour in a patient who declines or cannot tolerate surgery, image-guided ablation — radiofrequency, microwave or cryoablation — destroys the tumour through a needle puncture with millimetre accuracy, leaving the breast intact and requiring no incision of consequence. It is used in selected cases, always combined with assessment of the axillary nodes, and never as a way of avoiding proper staging. The robotic platform, with 10× magnified three-dimensional vision and tremor-free wristed instruments, is used where it improves precision in tissue that needs to be preserved.

  • No surgical incision
  • Breast shape unchanged
  • Outpatient procedure
  • Axillary assessment still performed

Reconstruction: planned before the operation, not after

Reconstruction is not a cosmetic afterthought appended to cancer treatment. It is a decision taken before surgery, because the technique chosen for removing the cancer determines what reconstruction is possible, and because the patient should know what she will wake up to.

  • Immediate reconstruction

    Performed at the time of the mastectomy. An implant or, where appropriate, the patient's own tissue is used to restore the breast in the same operation. The advantage is a single operation, a single recovery, and no interval without a breast. It requires that the tumour and treatment plan allow it, and it is discussed with the surgeon who will perform it rather than decided by the oncologist alone.

  • Delayed reconstruction

    Performed later, after completing radiotherapy or systemic therapy. It is the appropriate sequence when radiotherapy to the chest wall is planned, because radiotherapy alters the tissue that would carry the reconstruction. The trade-off is a longer overall course and a period without reconstruction, which many patients find the hardest part of the whole treatment.

  • Autologous tissue

    Uses the patient's own tissue to rebuild the breast. It gives a reconstruction that behaves like natural tissue, ages with the patient, and tolerates radiotherapy better than an implant. It involves a longer operation and a donor-site recovery, which is a real cost and should be stated as one.

  • What shapes the choice

    The size and location of the tumour, whether radiotherapy is planned, the patient's own tissue and general fitness, and above all what the patient wants. Symmetry of the opposite breast can be addressed at the same time or later. These are decisions where "what do you want to look like" is a clinical question, and asking it is part of the treatment.

Radiotherapy, and radiosurgery for recurrence

Radiotherapy after breast-conserving surgery reduces the risk of the cancer returning in the same breast, and after mastectomy it is used where the risk of chest-wall recurrence is elevated. Standard courses are delivered over several weeks; hypofractionated schedules complete the same treatment in fewer, larger fractions.

When the cancer returns in one place: radiosurgery instead of another operation

"There is a new spot in my chest wall, in a lymph node, or in my bone. Do I need another operation?"

Often not. CyberKnife M6 stereotactic radiosurgery delivers sub-millimetre precision — 0.1 mm — while tracking tumour motion in real time and converging beams from thousands of angles onto the target. Postoperative chest-wall recurrences, lymph node relapses and isolated bone or lung deposits can be ablated in one to five outpatient sessions, without an incision and without interrupting the systemic treatment already underway. Because dose falls away steeply outside the target, the heart and lungs receive very little — which is what makes it usable for lesions on the left side, close to the heart. Our hospitals have performed more than 1,000 CyberKnife treatments .

  • No incision
  • No interruption to drug treatment
  • 1–5 outpatient sessions
  • Heart and lung sparing

Learn more: CyberKnife stereotactic radiosurgery

Drug treatment: chosen by what the tumour carries

Systemic therapy is where breast cancer treatment has changed most in the past decade, and where the gap between what is approved in China and what is available elsewhere has narrowed markedly. Each group below is matched to a molecular finding rather than to a stage.

What the tumour carries Main drug groups used
Hormone receptor-positive, early Endocrine therapy for five to ten years — tamoxifen or an aromatase inhibitor, with ovarian function suppression in premenopausal patients where indicated; chemotherapy added only where the risk justifies it
Hormone receptor-positive, advanced Endocrine therapy combined with a CDK4/6 inhibitor, then further endocrine-based combinations at progression
HER2-positive Anti-HER2 antibody therapy with chemotherapy, given before or after surgery depending on stage; antibody-drug conjugates and bispecific antibodies when resistance emerges
HER2-low Antibody-drug conjugate therapy in previously treated disease — a group that was until recently treated as HER2-negative
Triple-negative Chemotherapy, with PD-1/PD-L1 blockade added where the tumour expresses the relevant marker; PARP inhibitors in BRCA-associated disease; antibody-drug conjugates in later lines
BRCA1 or BRCA2 germline mutation PARP inhibitor therapy in the appropriate setting, with genetic counselling for the family

On cost, stated plainly. Because these agents are developed and manufactured within China's own pharmaceutical ecosystem — including several that originated here — the comprehensive cost of a course of treatment is typically 30%–50% of what the same course would cost in Europe or the United States . For treatment that continues over years, that difference often determines whether a family can sustain it.

When the first drug stops working

Resistance is not a failure of the treatment that came before it; it is the expected behaviour of a disease that mutates. What determines the next step is not the name of the previous regimen but the molecular state of the tumour at the time it progressed.

  • Re-biopsy or blood-based sequencing

    A new biopsy of a progressing site, or circulating tumour DNA where biopsy is difficult, frequently reveals a change that was not present at diagnosis — an ESR1 mutation after endocrine therapy, or a new actionable alteration. The next drug follows from that result.

  • Antibody-drug conjugates

    These deliver cytotoxic payloads directly to cells bearing the target antigen, and they have changed outcomes in HER2-positive and HER2-low disease after prior therapy. Access in China is direct rather than deferred, which matters when the treatment is the next line rather than a future option.

  • Clinical trial access

    When approved options are exhausted, China runs a large portfolio of phase III trials — frequently with therapies that become available elsewhere three to five years later. Enrolment is matched by molecular profile, reviewed by an ethics committee, and conducted under full clinical supervision.

Finishing the full course: managing what stops patients

Breast cancer treatment extends over months or years, and the most common reason a patient cannot complete the planned course is not the cancer — it is the accumulated burden of side effects. Two of them are specific to breast cancer and both are treatable.

  • Lymphoedema after axillary surgery

    Swelling of the arm on the operated side is chronic, uncomfortable and, once established, difficult to reverse. Sentinel node biopsy has reduced how often extensive axillary surgery is needed, which reduces its incidence; where it occurs, early specialist management — physical therapy, compression, and targeted acupuncture and herbal protocols that address fluid stagnation and lymphatic circulation — is more effective than waiting for it to become established.

  • Treatment tolerance

    Nausea and vomiting, fatigue, and reduced blood counts are the side effects most likely to interrupt a chemotherapy schedule, and dose delays and reductions have a measurable cost in outcomes. Our integrative oncology service works alongside the primary treatment, using evidence-informed herbal formulations and acupuncture aimed specifically at these effects, with the goal of keeping every planned cycle on schedule.

Integrative treatment is given as support alongside standard oncology treatment, not as a substitute for it, and it is supervised by clinicians who know what the patient is receiving.

A single recommendation, delivered in 48 hours

Why breast cancer is decided in a meeting rather than an office

The best answer to a breast cancer question is usually a combination, and the order matters as much as the components: breast surgery, plastic and reconstructive surgery, medical oncology, radiation oncology, radiology and pathology each hold part of the decision. Our breast multidisciplinary panel reviews imaging, pathology and receptor results together and issues one written plan — not parallel opinions from separate departments. Send your records and receive that plan within 48 hours of the file being complete, whether you intend to travel or simply want a second opinion to use at home.

If you are still at the stage of establishing what you have rather than what to do about it, begin with how breast cancer is diagnosed. The underlying risk factors and how they can be modified are covered in causes and risk factors and prevention and screening.

Frequently Asked Questions

Do I have to choose between removing the cancer and keeping my breast?

In most early-stage cases, no — the two goals are compatible, and treatment is planned to achieve both. Breast-conserving surgery with clear margins followed by radiotherapy gives the same long-term survival as mastectomy in large randomised trials. Where the tumour is large relative to the breast, oncoplastic techniques reshape the remaining tissue in the same operation; where drug treatment is given first and the tumour shrinks substantially, conservation sometimes becomes possible when it was not at diagnosis. Mastectomy remains correct for some patients, but it should be a decision rather than a default.

What happens if the cancer comes back in one place?

An isolated recurrence — in the chest wall, a lymph node, or a single organ site — does not automatically require another major operation. Stereotactic radiosurgery can ablate a defined recurrence in one to five outpatient sessions without an incision and without stopping the systemic treatment already in progress. Where the site is accessible and few in number, image-guided ablation is another local option. The decision depends on how many sites are involved and whether the rest of the disease is stable, which is why the imaging is reviewed as a whole rather than one lesion at a time.

Why is drug treatment sometimes given before surgery rather than after?

Because the tumour's response to drugs is itself information. Giving treatment first can shrink a tumour enough to allow breast-conserving surgery, and the amount of residual disease at the time of the operation tells the team how sensitive the cancer is to that regimen — which guides what is given afterwards. This approach is used particularly in HER2-positive and triple-negative disease, where the response to pre-operative treatment has a measurable bearing on the plan that follows.

Is it worth travelling for treatment I could have at home?

Sometimes, and the honest criteria are access and cost rather than quality. If a drug you need is approved and affordable where you live, having treatment at home is usually better — nearer to family and less disruptive. The reason patients travel here is a gap in one of those two things: an agent not yet available at home, a waiting list that is longer than the disease allows, or a cost that makes a multi-year course unsustainable. Where that gap does not exist, our team will say so plainly.

Patient Stories

Stories from our breast cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Let our breast panel review your plan

Send your imaging, pathology and receptor results, together with the treatment already proposed. Our multidisciplinary breast team will return a written assessment within 48 hours of the file being complete — including whether a different sequence, a different agent, or an additional test is likely to change the outcome.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

WhatsApp +86 172-7459-8280 · EN / 中文 · 24h within business hours

Follow Fosun Health

Apply for an Appointment

Do you have test results*